An Acute, Double-blind, Placebo-controlled Cross-over Study Of 320 Mg And 640 Mg Doses Of Bacopa Monnieri (CDRI 08) On Multitasking Stress Reactivity And Mood
Notes for this study:
|Number of Subjects
In a randomized, double-blind, placebo-controlled crossover trial, 17 participants took placebo, 320 mg, or 640 mg of a Bacopa extract standardized for no less than 55% of bacosides before cognitive testing on separate occasions. The testing was a multitasking platform that required participants to simultaneously perform 4 cognitive tasks, including Mental Arithmetic, Stroop test, Letter Search, and Visual Tracking. Mood and stress were also measured.
There weren't notable differences between any of the treatments on the MTF test overall, though there were trends towards greater improvements in the Stroop and Letter score tests. There was greater alertness in the 320 mg group than placebo, and for the 640 mg group compared with baseline, while the difference wasn't statistically significant compared with placebo. Statistically significant differences weren't found for calmness, contentedness, or anxiety, but these were general trends towards improvement for the Bacopa conditions. There was a greater reduction in cortisol in the post-treatment phase for the highest dose of Bacopa, but not the smaller dose.